An Introduction to writing an Systematic review of literature - Scientific re...Pubrica
A systematic review is a type of literature review that uses a systematic method to collect Secondary data in which there is a comprehensive search for relevant studies on a particular topic, and those identified are then evaluated and synthesized according to a predetermined and explicit method.
This framework especially is essential for early career researchers and medical students to enhance their writing knowledge on the systematic review of the literature.
Why Pubrica:
When you order our services, we promise you the following – Plagiarism free, always on Time, outstanding customer support, written to Standard, Unlimited Revisions support and High-quality Subject Matter Experts.
Learn More: https://bit.ly/38jAbCT
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom : +44-1143520021
This workshop is meant to be an introduction to the systematic review process. Further information about systematic reviews was available through a research guide. http://libguides.ucalgary.ca/content.php?pid=593664
An Introduction to writing an Systematic review of literature - Scientific re...Pubrica
A systematic review is a type of literature review that uses a systematic method to collect Secondary data in which there is a comprehensive search for relevant studies on a particular topic, and those identified are then evaluated and synthesized according to a predetermined and explicit method.
This framework especially is essential for early career researchers and medical students to enhance their writing knowledge on the systematic review of the literature.
Why Pubrica:
When you order our services, we promise you the following – Plagiarism free, always on Time, outstanding customer support, written to Standard, Unlimited Revisions support and High-quality Subject Matter Experts.
Learn More: https://bit.ly/38jAbCT
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom : +44-1143520021
This workshop is meant to be an introduction to the systematic review process. Further information about systematic reviews was available through a research guide. http://libguides.ucalgary.ca/content.php?pid=593664
For a School of Information class on medical librarianship, this presentation was created to provide a very basic introduction and overview of the concepts, expectations, and experience of the librarian portion of working in a systematic review team.
A well recognised form of research is called systematic reviews on specific point. Why do we need them and How they can be done?? this talk is trying to answer these questions in a simple way
OHE’s Professor Nancy Devlin has researched, written and spoken widely on the use of the EQ-5D, and related measures, both in her capacity as the Director of Research at the OHE and as Chair of the Executive Committee of the EuroQol Group.
In May, Nancy was invited to participate in the “Workshop on measuring patient-reported outcomes using the EQ-5D”, which was organised by the Swedish National Board of Health and Welfare in collaboration with the EuroQol Group. The workshop brought together policy makers and researchers in Sweden interested in measuring patients’ health outcomes.
Sweden has included the EQ-5D in some of its quality registries and in population health surveys for many years. The Swedish National Board of Health and Welfare now is exploring whether and how to extend use of patient reported outcomes measures in the health care system, including the EQ-5D, to both monitor the quality of providers and services and to facilitate health technology appraisal.
Nancy’s talk, shown below, introduced the EQ-5D instrument; discussed how data from it can be analysed; identified some of the challenges in analysis; and commented on the future of outcomes measurement.
This PPT covers basics of Research Methodology like;
1. Meaning of Research
2. Nature of Research
3. Objectives of Research
4. Advantages of Research
5. Limitations of Research
6. Criteria / Features of Good Research
7. Types of Research
8. Process of Research
For a School of Information class on medical librarianship, this presentation was created to provide a very basic introduction and overview of the concepts, expectations, and experience of the librarian portion of working in a systematic review team.
A well recognised form of research is called systematic reviews on specific point. Why do we need them and How they can be done?? this talk is trying to answer these questions in a simple way
OHE’s Professor Nancy Devlin has researched, written and spoken widely on the use of the EQ-5D, and related measures, both in her capacity as the Director of Research at the OHE and as Chair of the Executive Committee of the EuroQol Group.
In May, Nancy was invited to participate in the “Workshop on measuring patient-reported outcomes using the EQ-5D”, which was organised by the Swedish National Board of Health and Welfare in collaboration with the EuroQol Group. The workshop brought together policy makers and researchers in Sweden interested in measuring patients’ health outcomes.
Sweden has included the EQ-5D in some of its quality registries and in population health surveys for many years. The Swedish National Board of Health and Welfare now is exploring whether and how to extend use of patient reported outcomes measures in the health care system, including the EQ-5D, to both monitor the quality of providers and services and to facilitate health technology appraisal.
Nancy’s talk, shown below, introduced the EQ-5D instrument; discussed how data from it can be analysed; identified some of the challenges in analysis; and commented on the future of outcomes measurement.
This PPT covers basics of Research Methodology like;
1. Meaning of Research
2. Nature of Research
3. Objectives of Research
4. Advantages of Research
5. Limitations of Research
6. Criteria / Features of Good Research
7. Types of Research
8. Process of Research
Edm forum virtual brown bag presentationMarion Sills
EDM Forum Virtual Brown Bag Presentation 2013
Overview of the SAFTINet Project
For more information on SAFTINet, please see http://www.ucdenver.edu/academics/colleges/medicalschool/programs/outcomes/COHO/saftinet/Pages/default.aspx
Data mining is a powerful method to extract knowledge from data. Raw data faces various challenges that make traditional method improper for knowledge extraction.
Data mining is supposed to be able to handle various data types in all formats.
Medical data mining is a multidisciplinary field with contribution of medicine and data mining.
each paper is studied based on the six medical tasks: screening, diagnosis, treatment, prognosis, monitoring and management.
Methods for Observational Comparative Effectiveness Research on Healthcare De...Marion Sills
Research Objective: The SAFTINet project was funded by the AHRQ to build a distributed network of existing clinical and claims data that would support comparative effectiveness research (CER), with a focus on underserved populations and healthcare delivery system (HDS) characteristics. Observational research methods are appropriate, but require detailed protocols with a priori hypotheses and analytic plans. SAFTINet research specifically concerns the effects of a discrete set of HDS features (those often included in Patient-Centered Medical Home (PCMH) models) on health outcomes for primary care patients with asthma, hypertension, and hypercholesterolemia. Our objective is to present a description of this study’s measurement challenges, and to specify a priori hypotheses, analytic strategies, and plans for addressing bias and confounding for our asthma cohorts.
Study Design: An observational, longitudinal cohort study of primary care patients with asthma, with both secondary use of existing clinical and claims data and primary data collection for HDS features and patient- reported outcomes.
Population Studied: Our sample consists of 59 primary care practices in 5 healthcare organizations in Colorado, Utah and Tennessee; all practices serve underserved populations. These practices care for about 275,000 patients per year, of whom an estimated 22,000 have a diagnosis of asthma.
Principal Findings: We will present the processes used to define and measure the HDS features, covariates and asthma outcomes, along with planned analysis. Challenges include valid measurement of a multi-faceted HDS “exposure” variable, the inability to identify exposure onset, and the non-dichotomous nature of HDS characteristics. To measure HDS characteristics, we created a practice-level survey assessing 9 PCMH domains, including care coordination, specialty care and mental health integration, and patient-centeredness, as well as asthma-specific HDS characteristics (e.g., the use of asthma registries). Asthma outcomes included (1) those available as a result of routine electronic documentation of clinical care and claims administration (utilization indicative of an exacerbation), and (2) patient reported outcomes tools (Asthma Control Test). We used directed acyclic graphs to identify potential confounders of the relationship between HDS characteristics and asthma control, as well as other potential biases. The analytic plan is based on linear mixed effects models. Perspectives of the CER team, the technology team and the community engagement group were considered in the operationalization of all variables.
Conclusions: The design of rigorous observational CER observational CER should recognize the need for an intense planning phase. In accordance with good practice guidance for observational studies, an important component of the planning phase is to disseminate and obtain feedback on the research design in advance of its conduct.
Computer validation of e-source and EHR in clinical trials-KuchinkeWolfgang Kuchinke
Clinical Trials in the Learning Health System (LHS): Computer System Validation of eSource and EHR Data.
The question that was addressed: How to make a clinical trial data management system that uses EHR data, Patient Reported Outcome (PRO) and eSource data as part of the Learning Health System compliant with regulations and with Good Clinical Practice (GCP)?
The Learning Health System (LHS) connects health care with translational and clinical research. It generates new medical knowledge as a by-product of the care process and its aim is to improve health and safety of patients. The LHS generates and applies knowledge. For this purpose, clinical research, which is research involving humans, must be part of the LHS. Two general types of research exists: observational studies and clinical trials.
Clinical data drive the LHS, because results from randomized controlled trials are seen as “gold standard” for medical evidence. For this reason the concept of using data gathered directly from the patient care environment has enormous potential for accelerating the rate at which useful knowledge is generated.
All computer systems involved in clinical trials must undergo Computer System Validation (CSV). For this process, a legal framework for the TRANSFoRm project was developed. It was used for data privacy analysis of the data flow in two research use cases: an epidemiological cohort study on Diabetes and a randomised clinical trial about different GORD treatment regimes.
Computerized system validation is the documented process to produce evidence that a computerized system does exactly what it is designed to do in a consistent and reproducible manner. The validation of electronic source data in clinical trials presents many challenges because of the blurring of the border between care and research. Here we present our approach for the validation of eSource data capture and the developed documentation for the CSV of the complete data flow in the LHS developed by the TRANSFoRm project. An important part hereby played the GORD Valuation Study.
Computer System Validation - privacy zones, eSource and EHR data in clinical ...Wolfgang Kuchinke
Clinical Trials in the Learning Health System (LHS): Computer System Validation of eSource and EHR Data.
The question that was addressed: How to make a clinical trial data management system that uses EHR data, Patient Reported Outcome (PRO) and eSource data as part of the Learning Health System compliant with regulations and with Good Clinical Practice (GCP)?
The Learning Health System (LHS) connects health care with translational and clinical research. It generates new medical knowledge as a by-product of the care process and its aim is to improve health and safety of patients. The LHS generates and applies knowledge. For this purpose, clinical research, which is research involving humans, must be part of the LHS. Two general types of research exists: observational studies and clinical trials.
Clinical data drive the LHS, because results from randomized controlled trials are seen as “gold standard” for medical evidence. For this reason the concept of using data gathered directly from the patient care environment has enormous potential for accelerating the rate at which useful knowledge is generated.
All computer systems involved in clinical trials must undergo Computer System Validation (CSV). For this process, a legal framework for the TRANSFoRm project was developed. It was used for data privacy analysis of the data flow in two research use cases: an epidemiological cohort study on Diabetes and a randomised clinical trial about different GORD treatment regimes.
Computerized system validation is the documented process to produce evidence that a computerized system does exactly what it is designed to do in a consistent and reproducible manner. The validation of electronic source data in clinical trials presents many challenges because of the blurring of the border between care and research. Here we present our approach for the validation of eSource data capture and the developed documentation for the CSV of the complete data flow in the LHS developed by the TRANSFoRm project. An important part hereby played the GORD Valuation Study.
Computer System Validation with privacy zones, e-source and clinical trials b...Wolfgang Kuchinke
Clinical Trials in the Learning Health System: Computer System Validation of eSource and EHR Data. Basic question is how to make a clinical trial data management system that uses EHR data, Patient Reported Outcome (PRO) and eSource data as part of the Learning Health System compliant with regulations and with Good Clinical Practice (GCP)? Computer System Validation (CSV) is a requirement for all computer systems involved in clinical trials for drug submission. It consists of documented processes to produce evidence that a computerized system does exactly what it is designed to do in a consistent and reproducible manner. Validation begins with the system requirements definition and continues until system retirement. For example, the components of a clinical trials
framework used in our case are: Patient eligibility checks and enrolment, pre-population of eCRFs with data from EHRs, PROM data collection by patients, storing of a copy of study data in the EHR, and validation of the Study System that coordinates all study and data collection events.
eSource direct data entry in clinical trials and GCP requirements. It is the duty of physicians who are involved in medical research to protect the privacy and confidentiality of personal information of research subjects. Any eSource system should be fully compliant with the provisions of applicable data protection legislation. This creates the need to develop and implement processes that ensure the continuous control of the investigators over these data. This has to be the focus of CSV. Clinical Data drive the LHS. The results from randomized controlled trials are seen as the “gold standard” for medical evidence, but such trials are often performed outside the usual system of care and recruit highly selected populations. For this reason, the concept of using data gathered directly from the patient care environment has enormous potential for accelerating the rate at which useful knowledge is generated.
This leads to the requirement for validating electronic source data in clinical trials. This includes validation for clinical data that is either captured from the subject directly or from the subject’s medical records. The problem is the correct and appropriate system validation of electronic source data. The main componenets of CSV are the Validation Master Plan), User Requirements Specification, Hardware Requirements Specification, Design qualification, Installation qualification, Operational qualification, Performance qualification.
Any instrument used to capture source data should ensure that the data are captured as specified within the protocol. Source data should be accurate, legible, contemporaneous, original, attributable, complete and consistent. An audit trail should be maintained as part of the source documents for the original creation and subsequent modification of all source data.
Data for Impact hosted a one-hour webinar sharing guidance for using routine data in evaluations. More: https://www.data4impactproject.org/resources/webinars/routine-data-use-in-evaluation-practical-guidance/
Clinical Research Informatics Year-in-ReviewPeter Embi
Peter Embi's 2018 Clinical Research Informatics Year-in-Review. Presented as closing Keynote address at the 2018 AMIA Informatics Summit in San Francisco, CA.
Operations research within UK healthcare: A reviewHarender Singh
The paper "Operations research within UK healthcare: a review" provides an overview of the application of operations research (OR) in the UK healthcare sector. The review highlights the contribution of OR in improving efficiency, reducing costs, and enhancing patient outcomes in various areas of healthcare, such as hospital management, patient flow, resource allocation, and scheduling. The paper also discusses the challenges and opportunities in applying OR in healthcare, such as data availability, ethical considerations, and stakeholder engagement. Overall, the review provides insights into the potential of OR to drive innovation and improve healthcare delivery in the UK.
Peter Embi's 2017 Clinical Research Informatics Year-in-Review. Presented as closing Keynote address at the 2017 AMIA Summits on Translational Science in San Francisco, CA.
Measuring and Enhancing Your Academic Medical ImpactMarion Sills
Overview of measuring and enhancing the impact of your scholarly work in academic medicine. The talk reviews how impact is defined and measured, how to improve your own impact metrics and how to describe the impact of your scholarly contributions to science.
Stakeholder Engagement in a Patient-Reported Outcomes Implementation by a Pra...Marion Sills
Kwan BM, Sills MR, Graham D, Hamer MK, Fairclough DL, Hammermeister KE, Kaiser A, Diaz-Perez MJ, Schilling LM. Stakeholder Engagement in a Patient-Reported Outcomes Implementation by a Practice-Based Research Network. JABFM. In Press.
Practice Variability in and Correlates of Patient-Centered Medical Home Chara...Marion Sills
Schilling LM, Sills MR, Fairclough D, Kwan MB. Practice Variability in and Correlates of Patient-Centered Medical Home Characteristics. SAFTINet Convocation. Aurora, Colorado. 13 Feb 2013.
Sills MR. Inpatient capacity margin at children's hospitals during the fall 2009 H1N1 influenza pandemic. Presentation to the Colorado Emergency Medicine Research Center. 14 June 2010.
Sills MR. Overview of the SAFTINet Program. Presented to the Emergency Department Research Committee, Department of Pediatrics, University of Colorado School of Medicine. 6 January 2015.
Patient-reported outcomes for asthma in children and adultsMarion Sills
Patient-reported outcomes for asthma in children and adults. Guided Discussion to Facilitate SAFTINet Stakeholders' Selection of an Asthma PROM. Teleconference. 1 April 2011
Sills MR. Cardiovascular Cohorts PROM Measures Updates and Action Items. Slides for teleconference to facilitate discussion of Cardiovascular PRO Measure Selection by SAFTINet Stakeholder Community. 21 March 2012.
Sills MR. Evolution of PRO Measure for Cardiovascular Cohorts in SAFTINet. Slides for teleconference to facilitate discussion of Cardiovascular PRO Measure Selection by SAFTINet Stakeholders. 2 May 2012.
Sills MR. Medication Adherence PROM Measures Updates and Pilot Results. Slides for teleconference to facilitate discussion of Cardiovascular PRO Measure Selection and Refinement by SAFTINet Stakeholders. 2 July 2012.
Sills MR. Medication Adherence PROM Measures and Self Efficacy. Slides for teleconference to facilitate discussion of Cardiovascular PRO Measure Selection by SAFTINet Stakeholders. 21 May 2012.
Cer safti net overview edrc 1 feb 2011Marion Sills
Sills MR. Overview of Comparative Effectiveness Research Using SAFTINet as an Example. Methods Talk presented to the Emergency Department Research Conference, Department of Pediatrics, 1 February 2011.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
2. Agenda
• Review CER research questions and
hypotheses
– Specific aims of the grant
– Conceptual model
– Refining hypotheses
– Sources of data
• Outline for systematic identification of data
domains and elements
3. Agenda
• Review CER research questions and
hypotheses
– Specific aims of the grant
– Conceptual model
– Refining hypotheses
– Sources of data
• Outline for systematic identification of data
domains and elements
4. Specific Aims of the Grant
• Specific Aim Related to CER (Aim 3): Develop
and enhance four sentinel cohort pairs of
patients with asthma (pediatric and adult),
hypertension, and hypercholesterolemia
distinguished by their care delivery
characteristics which can support
comparative effectiveness research.
5. Specific Aims of the Grant
• Overall Goals:
• Demonstrate the capability of the SAFTINet data
system to collect and accurately link relevant and
valid patient-level information necessary for
comparing the effectiveness of different delivery
system strategies
• Lay the groundwork (cohort identification,
outcomes measurement, sample size estimates,
etc.) to conduct prospective observational studies
and clinical trials
6. Specific Aims of the Grant
• The SPECIFIC SUB-AIMS for Aim 3 are:
– Specific Aim 3.1 Specify the data elements required
for optimal cohort creation.
– Specific Aim 3.2 Develop and use multivariable
models of asthma, blood pressure and cholesterol
control to identify system-level, individual care
provider-level, and patient-level factors associated
with the control of these conditions.
– Specific Aim 3.3 Enhance the data set by
implementing point-of-care data collection tools for
health-related quality of life.
7. Agenda
• Review CER research questions and
hypotheses
– Specific aims of the grant
– Conceptual model
– Refining hypotheses
– Sources of data
• Outline for systematic identification of data
domains and elements
8. Conceptual Model
Relatively
Mutable
CLINICAL INERTIA
Counseling
Drug selection
Dosage selection
Concomitant meds
Follow-up
Decision support
PATIENT-CENTERED
MEDICAL HOME
Integrated Mental
Health Care
Disease-specific case
mngmnt
Access to care
Outcomes feedback
THERAPY ADHERENCE
Therapy persistence
Mental health status
Health knowledge
Perceived need for
care
Symptoms
Drug side effects
PROCESSES OF
CARE
(clinician
factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic
disease
control)
Relatively
immutable
Appointment time
Patient load
Physical facilities
Practice type
Support personnel
Generalist vs.
specialist
Age
Gender
Race/ethnicity
SES
Marital status
Religious/cultural
beliefs
Comorbidity
9. Agenda
• Review CER research questions and
hypotheses
– Specific aims of the grant
– Conceptual model
– Refining hypotheses
– Sources of data
• Outline for systematic identification of data
domains and elements
10. Refining Hypotheses
• Hypothesis from Research Design: “We
hypothesize that health care delivery system
factors, such as the patient-centered medical
home, outweigh individual care provider
factors, patient factors, and medication
effectiveness in the control of asthma, high
blood pressure and hypercholesterolemia. “
11. Example Hypotheses
• Pediatric asthma outcomes (define) are better by
some amount X (define) at health centers that
implement PCMH functions (define specific
function(s)).
• A greater proportion of adult hypertension patients
with a dx of depression are appropriately controlled
at practices that have integrated mental health
services (IMH).
• The level (intensity) of IMH services is correlated
with improved BP control in adult HTN patients
whom also have a dx of depression.
12. Refining Hypotheses
CLINICAL INERTIA
Drug selection
Dosage selection
Concomitant meds
PATIENT-CENTERED
MEDICAL HOME
Intgrtd Mental Health
Disease-specific case
management
Access to care
THERAPY ADHERENCE
Therapy persistence
Mental health status
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
Generalist vs. specialist
Age, Gender
Race/ethnicity
SES
Marital status
Comorbidity
Hypothesis: health care delivery system factors, such as the patient-centered
medical home, outweigh individual care provider factors, patient factors, and
medication effectiveness in the control of asthma, high blood pressure and
hypercholesterolemia.
13. Refining Hypotheses
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
•Primary explanatory variable: patient-centered medical home
•Dependent variables: meeting national, evidence-based guidelines
for control
•Independent variables: Factors associated with disease control,
identified from literature, research experience, and clinical
judgment
•Statistical analysis: Mixed effects models will be used to determine
factors associated with chronic disease control; the primary
explanatory variable of the PCMH clinic, and the other factors
impacting chronic disease control
14. Agenda
• Review CER research questions and
hypotheses
– Specific aims of the grant
– Conceptual model
– Refining hypotheses
– Sources of data
• Sample data dictionary
• Outline for systematic identification of data
domains and elements
15. Sources of Data
• EHR
• Medicaid claims
• Enhanced point-of-care data collection
• Organizational or practice-level survey
16. Agenda
• Review CER research questions and
hypotheses
– Specific aims of the grant
– Conceptual model
– Refining hypotheses
– Sources of data
• Sample data dictionary
• Outline for systematic identification of data
domains and elements
19. Agenda
• Review CER research questions and
hypotheses
– Specific aims of the grant
– Conceptual model
– Refining hypotheses
– Sources of data
• Sample data dictionary
• Outline for systematic identification of data
domains and elements
20. Outline for Systematic Identification of
Data Domains and Elements
• Establish:
– Hypotheses and research questions
– Cohort definition
– Outcome measures
– Primary explanatory variable
– Covariates
• Establish these in order to:
– Make a list of needed data elements for current work
– Lay the groundwork for future directions
• Document a rationale for hypotheses and
selection of measures (constructs and data
elements)
21. Outline for Systematic Identification of
Data Domains and Elements
• An example from an asthma cohort
• Purpose of example to illustrate
– Selecting hypotheses and measures
– Listing data elements
– Documentation of a rationale for hypotheses and
selection of measures (constructs and data
elements)
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
22. Outline for Systematic Identification of
Data Domains and Elements
• Establish:
– Hypotheses and research questions
– Cohort definition
– Outcome measures
– Primary explanatory variable
– Covariates
• Establish these in order to:
– Make a list of needed data elements for current work
– Lay the groundwork for future directions
• Document a rationale for hypotheses and
selection of measures (constructs and data
elements)
23. Outline for Systematic Identification of
Data Domains and Elements
•Establish hypothesis: clinical inertia is
associated with worse asthma control
CLINICAL INERTIA
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
24. Outline for Systematic Identification of
Data Domains and Elements
•Primary explanatory variable: clinical inertia
•Dependent variables: meeting evidence-based
guidelines for control
•Independent variables: Factors associated with
disease control, identified from literature,
research experience, and clinical judgment
CLINICAL INERTIA
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
26. Outline for Systematic Identification of
Data Domains and Elements
• Establish:
– Hypotheses and research questions
– Cohort definition
– Outcome measures
– Primary explanatory variable
– Covariates
• Establish these in order to:
– Make a list of needed data elements for current work
– Lay the groundwork for future directions
• Document a rationale for hypotheses and
selection of measures (constructs and data
elements)
27. Cohort Definition
• Concept: patients with persistent asthma
• Options
– Research Design’s definition
– HEDIS criteria
– Adjusted HEDIS criteria
– Enhanced data collection
– Others
28. Cohort Definition
• Research Design: “As per the 2007 …EPR-3, we will
define persistent asthma as” > 1 of the following
criteria in 12 months
– > 1 prescriptions for an asthma maintenance therapy
– > 2 asthma-related ED visits
– > 1 asthma-related hospitalization
29. Cohort Definition
• HEDIS: > 1 of the following criteria in 12 months
– > 4 asthma medication dispensing events
– > 2 asthma medication dispensing events + 4 asthma-related
outpatient visits
– > 1 asthma-related hospitalization
– > 1 asthma-related ED visit
• Adjusted HEDIS criteria: improved validity if patients meeting
criteria for >2 consecutive years (Mosen et al., 2005)
• Enhanced data:
– Patient-entered chronic severity (kiosk) to assess current impairment and
future risk (Porter et al., 2004)
– Provider-entered assessment of severity
30. Data Elements for Cohort Definition
Construct Measure Elements Values Reference Data
Source
Cohort
definition
HEDIS definition of persistent
asthma 1: > 4 asthma
medication dispensing events in
12 months
Asthma medication
dispensed (date,
medication)
y/n HEDIS
manual
Claims
data
Cohort
definition
HEDIS definition of persistent
asthma 2: > 2 asthma
medication dispensing events +
4 asthma-related outpatient
visits in 12 months
Asthma medication
dispensed (date,
medication)
Asthma-related
outpatient visits
(date, ICD-9 code)
y/n HEDIS
manual
Claims
data
Cohort
definition
HEDIS definition of persistent
asthma 3: > 1 asthma-related
hospitalization in 12 months
Asthma-related
inpatient visits (date,
ICD-9 code)
y/n HEDIS
manual
Claims
data
Cohort
definition
HEDIS definition of persistent
asthma 4: > 1 asthma-related
ED visits in 12 months
Asthma-related ED
visits (date, ICD-9
code)
y/n HEDIS
manual
Claims
data
31. Rationale for Selection of Measures
The current HEDIS measure for asthma uses administrative data
collected during 1 year to identify patients with presumed
persistent asthma and evaluates controller therapy during the
next year. The current HEDIS asthma inclusion include a
significant portion of patients with intermittent asthma;1, 2 thus,
we chose to use the methods validated by Moser et al., who
adapted the HEDIS measure to require at least 2 consecutive
years meeting qualification criteria to identify persistent
asthma.3
1 Kozyrskyj AL, Mustard CA, Becker AB. Identifying children with persistent asthma
from health care administrative records. Can Respir J. 2004;11:141-145.
2 Cabana MD, Slish KK, Nan B, Clark NM. Limits of the HEDIS criteria in determining
asthma severity for children. Pediatrics. 2004;114:1049-1055.
3 Mosen DM, Macy E, Schatz M, et al. How well do the HEDIS asthma inclusion criteria
identify persistent asthma? Am J Manag Care. 2005 Oct;11(10):650-4.
32. Outline for Systematic Identification of
Data Domains and Elements
• Review
– Hypotheses and research questions
– Cohort definition
– Outcome measures
– Primary explanatory variable
– Covariates
– Other future directions
• Review these in order to
– Make a list of needed data elements for current work
– Lay the groundwork for future directions
33. Outcome Measures
• Patient-Reported Control Measures
• Utilization Measures
• Health-Related Quality-of-Life (HRQoL)
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
34. • Asthma Control Test (ACT) (Nathan et al. 2004)
• Childhood Asthma Control Test (Liu et al.
2007)
• Asthma Control Questionnaire (Juniper et al.
1999)
• Asthma Therapy Assessment Questionnaire
(ATAQ) control index (Vollmer et al. 1999) –
mentioned in Research Design
Patient-Reported Control Measures
35. Outcome Measures: Utilization Measures
• Ratio of controller to total asthma medications—
mentioned in Research Design
– > 0.5 is suggested cut-point
– better associated with utilization (ED visits) than is
HEDIS outcome measure
– Weighted vs. not
• HEDIS outcome measure
– prescription of at least one controller medication
– found to be more of a severity indicator than
quality/control measure
• Acute hospital visits (ED, inpatient)
36. Outcome Measures: HRQoL
• Asthma-Specific Quality of Life
– Mini Asthma Quality of Life Questionnaire (Juniper et
al. 1999a)
– Asthma Quality of Life Questionnaire (Katz et al. 1999;
Marks et al. 1993)
– ITG Asthma Short Form (Bayliss et al. 2000)
– Asthma Quality of Life for Children (Juniper et al.
1996)
– Others?
• Generic Quality of Life
– SF-36 (Bousquet et al. 1994)
– SF-12 (Ware et al. 1996)
37. Data Elements for Outcome Measures
Definition
Construct Measure Elements Values Reference Data
Source
Asthma
control
Childhood Asthma Control Test 7 components 0-27
(poor
control
<19)
Liu et al.
2007
POC
measure
Asthma
control
Ratio of controller to total
asthma medications
Asthma medication
dispensed (date,
medication)
0-1
(dichot
omize
at 0.5)
HEDIS
manual
Claims
data
Asthma
control
Acute hospital resource
utilization
Asthma-related
inpatient visits (date,
ICD-9 code)
# visits Claims
data
Asthma
control
Acute hospital resource
utilization
Asthma-related ED
visits (date, ICD-9
code)
# visits Claims
data
39. Outline for Systematic Identification of
Data Domains and Elements
• Establish:
– Hypotheses and research questions
– Cohort definition
– Outcome measures
– Primary explanatory variable
– Covariates
• Establish these in order to:
– Make a list of needed data elements for current work
– Lay the groundwork for future directions
• Document a rationale for hypotheses and
selection of measures (constructs and data
elements)
40. Primary Explanatory Variable
• Clinical inertia: “the failure of clinicians to
initiate or intensify drug therapy appropriately
in a patient with uncontrolled asthma, blood
pressure or cholesterol”
CLINICAL INERTIA
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
42. Data Elements for Primary Explanatory
Variable Definition
Construct Measure Elements Values Reference Data
Source
Clinical
inertia
Childhood Asthma Control Test 7 components, date 0-27
(poor
control
<19)
Liu et al.
2007
POC
measure
Clinical
inertia
Medications Asthma medication
dispensed (date,
medication)
Claims
data
44. Outline for Systematic Identification of
Data Domains and Elements
• Establish:
– Hypotheses and research questions
– Cohort definition
– Outcome measures
– Primary explanatory variable
– Covariates
• Establish these in order to:
– Make a list of needed data elements for current work
– Lay the groundwork for future directions
• Document a rationale for hypotheses and
selection of measures (constructs and data
elements)
45. Covariates
• Processes of Care
– Clinical inertia (primary
explanatory variable)
– Medication prescription
• Structures of Care
– Practice demographics
– PCMH, IMH
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
• Patient Factors
– Demographics, access
– Co-morbidity (medical,
mental health)
– Severity of illness
– Therapy adherence
46. Covariates
• Processes of Care
– Clinical inertia (primary
explanatory variable)
– Medication prescription
• Structures of Care
– Practice demographics
– PCMH, IMH
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
• Patient Factors
– Demographics, access
– Co-morbidity (medical,
mental health)
– Severity of illness
– Therapy adherence
47. Covariates
• Medical Comorbidity:
– “Chronic medical co-morbidity will be...grouped
into 30 comorbidities as described by Elixhauser
and Quan.” (AHRQ co-morbidity measures)
– Body Mass Index (do we need other measures for
children?)
– Smoking status (also 2nd hand smoke exposure?)
PROCESSES OF
CARE
(clinician factors)
+
STRUCTURES OF
CARE
(system factors)
+ PATIENT FACTORS →
OUTCOMES
(chronic disease
control)
Comorbidity
49. Data Elements for Comorbidity
Variable Definition
Construct Measure Elements Values Reference Data
Source
Medical
co-
morbidity
HCUP comorbidity measure ICD-9 codes from
encounters and
problem list
0-27
(poor
control
<19)
Liu et al.
2007
EHR
52. Outline for Systematic Identification of
Data Domains and Elements
• Establish:
– Hypotheses and research questions
– Cohort definition
– Outcome measures
– Primary explanatory variable
– Covariates
• Establish these in order to:
– Make a list of needed data elements for current work
– Lay the groundwork for future directions
• Documenting a rationale for hypotheses and
selection of measures (constructs and data
elements)
58. Patient Centered Med Home
Standards- NCQA
1. Access and Communication
2. Patient Tracking and Registry Functions
3. Care Management
4. Patient Self‐Management Support
5. Electronic Prescribing
6. Test Tracking
7. Referral Tracking
8. Performance Reporting and Improvement
9. Advanced Electronic Communications
61. System Level Factors
• Applied differently based on
patient/family/doctor-- can we account for
this or not??
62. Considerations for Future Research
Asthma:
• Asthma epidemiology has focused on individual-
level and family risk factors.
• Less focus on social and environmental context.
• Low-income individuals more likely to be exposed
to irritants, pollutants, indoor allergens, and
psychosocial stress, which may influence asthma
morbidity.
• Future vision: enhance our cohort with data on
suspected biological and environmental
determinants of asthma disparities.
63. Considerations for Future Research
Hypertension:
• Prevalence and rate of diagnosis of hypertension
in children and adolescents are increasing, due in
part to the increasing obesity prevalence and
growing awareness of hypertension.
• Future vision: expand our cohort to include
adolescents with hypertension in an effort to
identify health care delivery strategies
appropriate for the lifespan of patients with
hypertension.
64. Considerations for Future Research
Hypercholesterolemia:
• American Academy of Pediatrics recommends
screening overweight children with a fasting
lipid profile
• Rising obesity epidemic in U.S. children
• Future vision: expand our
hypercholesterolemia cohort to include
overweight children.
Editor's Notes
Here are the data elements for one measure—the HEDIS measure—for the cohort definition construct. The HEDIS measure for persistent asthma has four components, each with 1-2 component elements.
To help illustrate the processes involved in constructing cohorts and associated data elements, we will run through a hypothetical hypothesis for an asthma cohort.
Would also need to include rationale for hypothesis
The cohort definition is meant to capture patients with persistent asthma. There are several options proposed in the Research Design and in other sources for how to define a cohort of patients with persistent asthma. These are summarized here, and shown in slightly more detail on the next 2 slides.
Here are the data elements for one measure—the HEDIS measure—for the cohort definition construct. The HEDIS measure for persistent asthma has four components, each with 1-2 component elements.
Here is a sample rationale-statement for the selection of one measure: the 2-consecutive-year version of the HEDIS definition of persistent asthma
There are several options proposed in the Research Design and in other sources for how to define outcomes indicative of asthma control. These are summarized here, and shown in slightly more detail on the next 3 slides. We would need to select from these (and other) measures.
This list includes some of the pt-reported control measures; we would select one of these for implementation at the POC. We would need to provide a rationale for the selection.
There are several measures of asthma control based on healthcare resource utilization; this slide is a partial list.
HRQoL is another construct that would fall into the Outcome Measures category. We would need to determine whether we will be using a disease-specific measure or a general measure for all cohorts, and then provide rationale for the specific selection
These are data elements needed for a few of the asthma-related outcome measures
As this is only an example we will not provide rationale statements for each type of data element
Our primary explanatory variable is clinical inertia; this slide shows the definition from the Research Design.